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ihe Vascular-Hypertension-Prevention (VHP) track in-
ludes data on vascular biology, hypertension, lipids, hor-
ones, thrombosis, and cardiovascular epidemiology and
rovides insight into the prevention and treatment of
oronary heart disease (CHD) and cerebrovascular and
eripheral artery disease. On behalf of my colleagues on the
cientific Program Committee, I am privileged to present
ighlights on VHP from the Scientific Presentations at the
nnual Scientific Sessions of the American College of
ardiology (ACC), held in New Orleans in March 2004.
revention. LIPIDS. The Thrombolysis In Myocardial In-
arction (TIMI)-22 trial was presented by C. P. Cannon
nd was an international multi-center trial involving 4,162
atients with an acute coronary syndrome (ACS) who were
andomized to moderate intensive lipid therapy with 40 mg
ravastatin versus high-intensity therapy with 80 mg ator-
astatin and followed for two years (1). Median low-density
ipoprotein (LDL) cholesterol at baseline was 106 mg/dl in
oth groups and fell to 95 mg/dl in the pravastatin group
nd to 62 mg/dl with high-dose atorvastatin. At two years,
,001 major cardiovascular (CV) events occurred, including
ll-cause mortality, myocardial infarction (MI), unstable
ngina, revascularizations, and stroke; there was a significant
6% reduction in major CV events in patients treated with
ntensive therapy (80 mg atorvastatin), including a 34%
vent reduction in those with baseline LDL cholesterol
125 mg/dl. A 17% benefit was noted as early as 30 days
nd became statistically significant by six months. These
esults challenged the current Adult Treatment Panel
ATP) III lipid guidelines to get LDL 100 mg/dl in
atients with CHD and suggest that LDL should be
owered to80 mg/dl and possibly as low as 60 to 70 mg/dl
n patients with ACS.
In other late-breaking clinical trials on lipids, M. Koren
resented the Alliance Study, in which 2,442 hyperlipid-
mic patients with CHD were randomized to atorvastatin to
ttain an LDL cholesterol 80 mg/dl versus usual care;
torvastatin lowered LDL cholesterol better (34% vs.
23%, p  0.0001) and was associated with a 17%
eduction in major CV events (p  0.02). P. S. Sever
resented data on diabetes in the Anglo-Scandinavian
ardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-
LA). In the entire ASCOT trial, diabetic patients did not
eem to obtain as much benefit as other patients. In 2,532
iabetic patients randomized to 10-mg atorvastatin versus
lacebo, LDL cholesterol was lowered by 40% with atorva-
tatin and total CV events were reduced by 23% (p  0.04),
From the Department of Cardiovascular Diseases and Internal Medicine, Ochsner
tlinic Foundation, New Orleans, Louisiana.learly demonstrating the benefits of atorvastatin in diabetic
atients (2).
Charakida et al. (3) presented data on 70 children with
uman immunodeficiency virus (HIV): 28 without anti-
etroviral treatment, 25 receiving treatment but no protease
nhibitors (PIs), and 17 receiving PIs. Total cholesterol was
levated in both treatment groups, but endothelial function,
s assessed by flow-mediated dilation (FMD), was only
mpaired in the PI group. This demonstrates that PIs are
ssociated with both dyslipidemia and endothelial dysfunc-
ion. Because of a lack of metabolism by the cytochrome
450 system, pravastatin is theoretically the safest statin to
ombine with HIV medications (4). In another study of 20
IV patients treated with PIs, Stein et al. (5) presented on
he effects of 40 mg pravastatin versus placebo, demonstrat-
ng that pravastatin improves atherogenic lipoprotein frac-
ions and endothelial function in HIV patients taking PIs.
BESITY. In one of the late-breaking clinical trials, data on
he endocannabinoid system was presented by L. Dale and
. Anthenelli, with discussion of rimonabant, a new
annabanoid-1 (CB) receptor antagonist used to aid smok-
ng cessation and weight reduction. This drug was helpful in
moking cessation (28% vs. 15%) and prevented weight gain
n these patients. In obesity, rimonabant led to a 20-lb
eight loss, 3-inch waist reduction, 25% increase in
igh-density lipoprotein (HDL) cholesterol, 50% fall in
riglycerides, and significant reductions in the metabolic
yndrome and C-reactive protein (CRP) of 50% and 27%,
espectively. Obesity is certainly not benign in the CV
ystem (6). In addition to the adverse CV effects of obesity,
alcox et al. (7) reported on 418 patients and demonstrated
he association of endothelial dysfunction with obesity,
ndependent of CRP, atherosclerosis, and conventional
HD risk factors.
ETABOLIC SYNDROME AND DIABETES MELLITUS (DM).
alik et al. (8) reported on 6,451 subjects and demon-
trated that the odds of CV disease markedly increased
hen two metabolic risk factors were present, especially in
hose with DM. It was shown that CRP was an indepen-
ent risk factor for CV disease, and CRP increased the risk
ven in those with DM. Desai et al. (9) reported on 6,142
ndividuals and demonstrated that the combination of
etabolic syndrome and lack of physical activity was asso-
iated with an incremental increase in subclinical athero-
clerosis, as determined by coronary calcium. Chen et al. (10)
xamined 1,474 children in the Bogalusa Heat Study with
6-year follow-up and determined that metabolic syndrome
isk factors in childhood predicted the metabolic syndrome
n adulthood and higher odds of parenteral CHD, hyper-
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ACC 2004 Annual Session Highlights July 21, 2004:19A–22Ahickness in adulthood. Deedwania et al. (11) reported on
11 patients with metabolic syndrome from Statin Thera-
ies for Elevated Lipid Levels compared Across doses to
osuvastatin (STELLAR), who were randomized to vari-
us doses of four different statins. Although lipids improved
ith all agents, rosuvastatin had the most favorable effects
n LDL, triglycerides, non-HDL, and HDL in these
igh-risk patients with the metabolic syndrome.
In 16,203 patients with DM in a registry, Lavasani et al.
12) reported that the use of triglidazones (TZDs) and
etformin was associated with marked reductions in mor-
ality, as compared with those receiving sulfonureas or
nsulin. In a late-breaking clinical trial, EUropean trial on
eduction Of cardiac events with Perindopril in patients
ith stable coronary Artery disease (EUROPA), K. M. Fox
eported on 1,502 with DM with CHD and no heart
ailure, who were randomized to 8-mg perindopril versus
lacebo, and demonstrated a 19% reduction in major CV
vents with this angiotensin-converting enzyme (ACE)
nhibitor in both those with and without DM (the number
eeded to treat was only 35 in those with DM). Similar to
ata with ACE inhibitors in Heart Outcomes Prevention
valuation (HOPE), Yusuf et al. (13) reported on 5,436
atients with HF and without DM from Candesartan
ilexitil in Heart failure Assessment of Reduction Mortality
nd morbidity (CHARM) and demonstrated that candesar-
an, an angiotensin receptor blocker, reduced DM by 12% in
hose taking an ACE inhibitor and significantly reduced
M by 29% in those not taking an ACE inhibitor.
ORMONES. Currently, hormone replacement therapy has
allen on hard times. Despite benefits on lipids and endo-
helial function, high-dose estrogen therapy is associated
ith increased CRP, hypercoagulable states, and increases
n major CV events. Koh et al. (14) randomized 57 women
o either 0.625 mg or 0.3 mg of conjugated equine estrogen;
oth groups received 100 mg of micronized progesterone.
oth high- and low-dose estrogen had comparable benefits
n lipoproteins, FMD, and plasminogen activator
nhibitor-1 levels. However, low-dose estrogen therapy did
ot increase CRP or prothrombin fragments and decreased
nti-thrombin III to a lesser extent than did high-dose
strogen.
Malkin et al. (15) assessed 20 men with a testosterone
eficiency and CHD and demonstrated that testosterone
eplacement therapy had modest and insignificant reduc-
ions in cholesterol, but significantly reduced inflammatory
arkers. Because 23% of men with CHD have hypogonad-
sm, they concluded that testosterone replacement may
mprove CHD as well as quality of life. In 724 dialysis
atients followed for two years, Itoh et al. (16) demon-
trated that brain natriuretic peptide (BNP) was the stron-
est independent variable to predict mortality. Van de Werf
t al. (17) reported the effects of pexelizumab, a C-5
omplement inhibitor, in 3,631 bypass and 1,274 ACS
atients treated with reperfusion and demonstrated that sexelizumab reduced mortality by 31% in these CHD
atients.
OLISTIC. The ATP III guidelines stress therapeutic life-
tyle changes (TLC) as initial therapy for high-risk patients.
ordon et al. (18) studied TLC in patients with hyperten-
ion, hyperlipidemia, and elevated fasting glucose and dem-
nstrated that two-thirds achieved their systolic and dia-
tolic blood pressure (BP) goals, 27% achieved that ATP III
DL goal, and 41% achieved their fasting glucose goal with
LC. These data support the benefits of TLC without
edications in preventive cardiology. The American Heart
ssociation has focused on their Get With the Guidelines
GWTG) campaign in patients with CHD. Ellrodt et al.
19) studied data on 160 hospitals and demonstrated that
WTG programs improved quality of care in various age
roups studied.
THER. Boger et al. (20) and Boger et al. (21) from
ermany reported on two studies on asymmetric dimethy-
arginine (ADMA), an endogenous inhibitor of nitric oxide
ynthase. In one study of 408 patients and 408 control
ubjects, CHD patients had high ADMA, and ADMA was
ignificantly increased with established CHD risk factors
nd was an independent marker for CHD (20). In a second
tudy of 15 elderly with elevated ADMA, 40 mg simvastatin
id not improve endothelial function, but L-arginine, more
o in combination with simvastatin, significantly improved
ndothelial function in these patients (21).
ypertension (HTN). In 22,576 patients with HTN and
HD in data from the late-breaking clinical trial Interna-
ional Verapamil-Trandolapril Study (INVEST), F. H.
esserli evaluated levels of on treatment BP and outcome
nd demonstrated a J-shaped mortality curve with high
vents in BP strata 140/90 mm Hg and 110/70 mm Hg
and possibly 120/80 mm Hg). Low diastolic BP was
ssociated with more MI, but not a high risk of stroke.
hese results increase our awareness of the potential adverse
ffects of an overzealous reduction in BP in patients with
HD. In 12,763 men from the Seven Country Study,
anagiotakos et al. (22) demonstrated that among all BP
easurements, pulse pressure was the strongest predictor of
V mortality, with hazard ratios from 1.06 to 1.17 per 5
m Hg (p  0.05).
Two papers were highlighted from the Losartan Inter-
ention For Endpoint reduction in hypertension (LIFE)
rial (23,24). Wachtell et al. (23) presented data on 9,193
atients followed for five years, and 190 sudden cardiac
eaths (SCDs) occurred. Baseline left ventricular hypertro-
hy (LVH) predicted SCD independent of CHD and other
isk factors and remained predictive in patients without
bvious atherosclerosis. Both losartan and atenolol pro-
ected equally against SCD. Okin et al. (24) looked at 8,254
ypertensive subjects, including 6% African Americans
ollowed for five years, and demonstrated that African
mericans had three times more LVH with strain (28% vs.
0%, p 0.001). In the non-African Americans, LVH with
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July 21, 2004:19A–22A ACC 2004 Annual Session Highlightsfrican Americans. In 529 rural men from the Corfu cohort
f the Seven Country Study during 40-year follow-up,
anogiotakos et al. (25) demonstrated that LVH increased
he risk of stroke by fivefold (p  0.001); high levels of
tness were associated with 35% lower risk of stroke (p 
.05), and high fitness reduced stroke by 24% in those with
VH (p  0.01). Shengxu et al. (26) presented data on 839
oung adults from the Bogalusa Heart Study during a
7-year follow-up period and demonstrated that childhood
ystolic BP, adult systolic BP and triglycerides, and cumu-
ative systolic BP and triglycerides predicted brachial-to-
nkle pulse-wave velocity, and that childhood systolic BP
as a consistent independent predictor of arterial stiffness in
dults. Finally, Berman et al. (27) studied 39 patients with
TN and percutaneous renal artery intervention and dem-
nstrated that this therapy reduced QT dispersion by50%
p  0.0001), improving ventricular refractoriness to a
reater degree than the decrease in BP and LVH would
uggest.
ascular. VENOUS THROMBOSIS AND PULMONARY HYPER-
ENSION. Giovanni et al. (28) studied 458 patients ran-
omized to control, aspirin for three days, or low-
olecular-weight heparin (LMWH) 2 to 3 h before a long
ight and found 5.6% deep venous thrombosis (DVT)
vents in controls, 4.3% in those taking aspirin, and no
vents in those receiving LMWH, thus demonstrating the
otential benefits of one fixed dose of LMWH as an option
or high-risk patients during long-haul flights. Kucher et al.
29) reported for the DVT Free Steering Committee on a
83-center U.S. registry of 5,451 consecutive patients (47%
en) and demonstrated that men received more DVT
rophylaxis than did women (34% vs. 29%, p  0.001).
lthough this year’s ACC meeting emphasized heart
isease prevention and treatment in women, this study
dentified a gender bias against women, with failure to
dminister DVT prophylaxis to high-risk women who
ubsequently developed DVT.
Pulmonary hypertension has major effects on morbidity
nd mortality. Lang et al. (30) studied 112 patients with
ulmonary hypertension treated with long-term treprostinil,
prostacyclin analog. This therapy improved exercise ca-
acity, reduced symptoms, and significantly improved over-
ll mortality.
THER VASCULAR. Kipshidze et al. (31) reported on 23
atients with significant limb ischemia who received either
ontrol therapy (saline), intramuscular fibrin, or fibrin plus
eferoxamine and added growth factor. Below-the-knee
mputation occurred in 70% in the control group, 33% with
brin, and only 10% with fibrin and growth factor, suggest-
ng that fibrin is a safe and potentially novel method for
nducing therapeutic angiogenesis in limb ischemia.
In a study of mice treated with or without rosiglitazone,
peroxisome proliferator-activated receptor agonist, Wang
t al. (32) demonstrated that rosiglitazone promoted differ-
ntiation of bone marrow-derived angiogenic progenitor
ells (APCs) toward endothelial lineage, enhanced APComing to injured vascular sites, and attenuated restenosis
ith angioplasty. Arterial stiffness was measured in 118
frican Americans and 285 Caucasian young adults in the
ogalusa Heat Study, and Chen et al. (33) reported that
894T polymorphism at the endothelial nitric oxide syn-
hase gene locus was associated with lower arterial wall
tiffness, independent of BP, and was especially present in
he African American cohort. Finally, Kunz et al. (34)
tudied 122 patients undergoing cardiac catheterization and
emonstrated that circulating endothelial progenitor cells
redicted the severity of disease in patients with multivessel
isease and DM, as well as in post-MI patients.
eprint requests and correspondence: Dr. Carl J. Lavie,
chsner Heart and Vascular Institute, 1514 Jefferson Highway,
efferson, Louisiana 70121-2483. E-mail: clavier@ochsner.org.
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